Custom Peptide Synthesis: Common Challenges and Solutions from Synthesis to Purification

Understanding Custom Peptide Synthesis

Custom peptide synthesis is the chemical assembly of a user-defined amino acid sequence into a single-chain molecule of defined length, composition, and purity. It is a foundational technology for modern drug discovery, structural biology, vaccine design, diagnostic assay development, and chemical biology probe construction. Every year, laboratories around the world order millions of such sequences ranging from short epitopes of six to ten residues to long functional proteins exceeding one hundred residues, and the success of each order depends on a clear understanding of how sequence composition translates into synthetic tractability.

The modern workflow is overwhelmingly based on solid-phase peptide synthesis (SPPS), a method in which the growing chain is anchored to an insoluble resin while protected amino acids are added one at a time from the C-terminus to the N-terminus. Because the peptide remains bound to the support throughout assembly, excess reagents can be washed away by simple filtration after every reaction, which drives couplings to completion and makes the process automatable. Two protecting schemes dominate the field: the Fmoc/tert-butyl strategy, which is deprotected under mild base, and the Boc/benzyl strategy, which is deprotected under strong acid. The Fmoc/tert-butyl strategy is the more widely used of the two in contemporary research and discovery settings because its final deprotection conditions are compatible with most modified side chains and it can be performed entirely on a standard automated synthesizer.

What Is Custom Peptide Synthesis?

A custom synthesis project starts with a defined sequence, a defined purity target, a defined quantity, and a defined set of analytical deliverables. From there, the chemist chooses a resin, a protecting scheme, a coupling chemistry, and a cleavage strategy, then plans purification, characterization, and packaging around the application. The deliverable is rarely a single molecule; it is a sample of well-characterized peptide at a stated purity, accompanied by chromatographic and mass spectrometric evidence that the requested sequence was actually produced. For most research uses, purity targets between 85 % and 98 % are routine, while applications such as receptor crystallography, quantitative bioassays, or quantitative mass spectrometry experiments typically require 95 % or higher, and sometimes more than 99 %.

Key Factors That Determine Peptide Synthesis Difficulty

Difficulty in custom peptide synthesis is not random. It follows the sequence itself, and an experienced chemist can read a sequence and predict where the bottlenecks will appear. The four most important predictors are summarized below.

• Chain length: each additional residue adds a coupling, a deprotection, and a wash cycle, so the cumulative yield falls as length grows. Peptides above roughly 30 residues begin to show measurable yield loss, peptides above 50 residues frequently require fragment assembly or ligation, and peptides above 80 residues are generally outside the reach of single-chain SPPS.
• Sequence composition: stretches of hydrophobic residues such as Val, Ile, Leu, Phe, Tyr, and Trp promote inter-chain aggregation on the resin; Arg-rich stretches bring coupling difficulties; Pro introduces cis–trans isomerism; and Cys residues require careful protection to avoid scrambling.
• Modifications: phosphorylation, glycosylation, lipidation, fluorescent labels, biotin, staple rings, and unnatural amino acids each introduce specific chemical steps that must be built into the synthesis plan from the beginning.
• Purity target and scale: a 5 mg research sample at 85 % purity is a very different project from a 500 mg sample at 98 % purity, and the resources devoted to purification, characterization, and documentation scale accordingly.

Table.1 Sequence Features and Their Typical Impact on Synthesis Difficulty.

Common Peptide Synthesis Challenges and Their Solutions

Most synthesis failures are not caused by exotic chemistry. They are caused by a small set of recurring sequence-dependent problems that an experienced chemist anticipates and prevents. The subsections below describe the six most common failure modes, the underlying mechanisms, and the practical strategies used to overcome them.

Aggregation and Inter-Chain β-Sheet Formation During Chain Assembly

Aggregation is the single most common reason a "normal-looking" sequence fails to deliver. As the resin-bound peptide grows, hydrophobic segments, particularly runs of Val, Ile, Leu, Phe, Tyr, and Trp, fold into transient inter-chain β-sheet structures that bury the N-terminal amine and block access for the next coupling. The result is a sudden drop in stepwise yield, accumulation of deletion byproducts, and a cruded peptide profile dominated by truncations. Three interventions are routinely used. First, the affected positions are coupled as pseudoproline dipeptides, which insert a threonine or serine residue as a reversible oxazolidine that disrupts β-sheet formation. Second, the deprotection step is performed in the presence of chaotropic additives such as urea or with extended piperidine contact time, weakening hydrogen-bonded aggregates before the next coupling. Third, couplings are executed at elevated temperature, often 50–65 °C, where the kinetics of coupling outpace the kinetics of refolding. These three measures, used in combination, allow sequences that would otherwise stall to reach the full target length with acceptable yield.

Incomplete Coupling and Deletion Sequence Byproducts

Every coupling is a chemical reaction with an equilibrium, and any coupling that does not reach near completion leaves an N-terminus that is capped by the next deprotection step, generating a permanent deletion sequence. Deletions are particularly difficult to remove in purification because they typically differ from the target by only a few residues, and their retention times in reversed-phase HPLC often overlap. The standard prevention strategy is double coupling at every step, with a third coupling by a different reagent system wherever a difficult residue is encountered. Common coupling reagent systems include DIC/HOBt, HBTU/HOBt, HATU/HOAt, and PyBOP, and switching from a uronium reagent to a phosphonium reagent (or vice versa) can rescue positions where the first chemistry stalls. In addition, capping with acetic anhydride after every coupling step permanently acetylates any unreacted chain, converting potential deletions into early-eluting, easily separated impurities rather than near-isobaric byproducts.

Racemization During Amino Acid Activation and Coupling

Activation of an amino acid at its carboxyl group can partially invert its α-carbon, and the inverted isomer is incorporated into the growing chain as a permanent epimer. For most residues the level of racemization is small and tolerable, but for Cys and His, where the side chain assists in the mechanism, racemization can become significant. The accepted mitigation is the use of additives that suppress the oxazolone intermediate, particularly HOAt in combination with HATU or COMU, combined with the use of preformed Fmoc-amino acid fluorides or symmetric anhydrides where the chemistry permits. For Cys specifically, the trityl (Trt) protecting group is preferred because it both reduces racemization and remains stable through the chain assembly steps. The risk of racemization is also why the choice of coupling reagent matters more than the choice of solvent for these residues.

Sequence-Dependent Challenges with Difficult Residues

Certain residues are recognized as intrinsically difficult: Arg because its guanidinium side chain creates a sterically congested coupling environment; Pro because it lacks an amide proton and must be coupled efficiently as the incoming residue; Cys because of its free thiol reactivity; and Asp/Gly combinations because of their tendency to form aspartimide, a side-reaction that simultaneously truncates the peptide and generates a succinimide. For Arg-rich sequences, the practical response is double coupling with HATU/HOAt, an extended coupling time, and, where necessary, the use of microwave-assisted coupling that supplies controlled energy directly to the reaction. For Asp/Gly, the standard prevention is the use of Hmb (2-hydroxy-4-methoxybenzyl) backbone protection on the residue preceding the Asp, which removes the amide proton responsible for the intramolecular cyclization. When these measures are applied, the difficult residue becomes a manageable step rather than a project-ending event.

Long Peptide Synthesis and Cumulative Yield Loss

The stepwise yield of a standard Fmoc-SPPS coupling is typically between 99.0 % and 99.7 %, which sounds excellent until the numbers compound. Across 30 residues at 99.5 % per step the overall isolated yield is roughly 86 %; across 50 residues it falls to 78 %; across 80 residues it is only 67 %; and across 100 residues it is below 60 %. The cumulative yield is the reason long peptide synthesis is treated as its own discipline rather than as a routine extension of standard synthesis. Three strategies are used. The first is fragment condensation, in which the target is divided into two or three protected fragments that are individually purified and then coupled together in solution or on a special resin. The second is native chemical ligation (NCL), in which a C-terminal thioester fragment and an N-terminal cysteine fragment are joined through a thiol-mediated transesterification followed by an S→N acyl shift that regenerates a native peptide bond. The third is the use of enhanced coupling conditions, including microwave-assisted SPPS and pseudoproline dipeptides, that raise stepwise yield above 99.7 % and reduce cumulative loss. For peptides longer than about 80 residues, NCL is generally the most reliable route, and the sequence is designed from the start with an N-terminal cysteine at the ligation site.

Incorporating Modified and Unnatural Amino Acids

The incorporation of a non-standard residue, whether an unnatural backbone, a D-amino acid, a β-amino acid, or a side-chain modification such as a phosphorylated serine, can be accomplished within SPPS as long as the building block is available as an Fmoc-amino acid with the appropriate orthogonal protecting groups. Phospho-Ser, phospho-Thr, and phospho-Tyr are commercially available as their fully protected Fmoc-monomers and are typically introduced as a single residue with double coupling and HATU/HOAt activation. Because modified peptide synthesis often requires building blocks that are expensive or fragile, the position and timing of incorporation is chosen to minimize both the cost and the cumulative exposure to repetitive coupling cycles. For sequences that contain more than two or three modified residues, fragment condensation is often preferable, because the modified fragment can be assembled, purified, and characterized on its own before ligation.

The table below consolidates the six synthesis challenges discussed in this section and pairs each one with its root cause and a recommended solution, providing a quick reference for sequence triage before a project begins.

Table.2 Common Peptide Synthesis Challenges and Recommended Solutions.

Common Peptide Modification Challenges and Their Solutions

Most peptides ordered today are not simple linear sequences. They carry post-translational modifications, conformational constraints, reporter tags, or affinity handles, and each class of modification brings its own synthetic logic. The four classes below are the most frequently requested and illustrate how each modification is integrated into the synthesis plan.

Phosphorylated and Glycosylated Peptides

Phosphorylation is the most common post-translational modification found in regulatory peptides, signaling motifs, and kinase substrates. It is introduced either by global phosphorylation of a free serine, threonine, or tyrosine residue after chain assembly (often with poor selectivity and low conversion) or, more reliably, by direct incorporation of the protected Fmoc-phospho-amino acid during SPPS. The global approach is convenient but rarely gives a single well-defined product; the building-block approach gives a defined stoichiometry at a defined position but requires that the protected phospho-monomer be coupled efficiently into a sequence that is often already sterically demanding. Glycosylation is similar in principle but more complex in practice: O-linked glycosylation can be incorporated as a preformed Fmoc-Ser/Thr building block carrying the protected sugar, while N-linked glycosylation requires the asparagine side chain to carry a chitobiose-type disaccharide that survives the entire synthesis and the final acidic cleavage. Both modifications demand rigorous confirmation by mass spectrometry, and phosphorylated peptides in particular benefit from phosphorus-specific detection during analysis.

Cyclic, Stapled, and Branched Peptide Architectures

Constrained peptides, including head-to-tail cyclic peptides, disulfide-cyclized peptides, lactam-bridged cyclic peptides, and stapled peptides built from olefin-bearing amino acids, are increasingly important because they lock the backbone into a bioactive conformation and resist proteolytic degradation. Head-to-tail cyclization is performed on a low-loading resin after side-chain deprotection; lactam bridges are installed by side-chain-to-side-chain or side-chain-to-N-terminal amine coupling during the synthesis; and stapled peptides are assembled with Fmoc-amino acids bearing olefin-bearing side chains, followed by ring-closing metathesis on the resin or after cleavage. Each architectural class requires the cyclization step to be efficient, because the failure modes are visible immediately as linear open-chain impurities that are difficult to separate from the cyclic product. Branched peptide synthesis follows a different logic: a second chain is built from an Fmoc-Lys(Fmoc) scaffold, and the branches are elongated in parallel by repeated coupling cycles, with careful monitoring of completeness at every branching point.

Fluorescent, Biotinylated, and Affinity-Labeled Peptides

Reporter and affinity tags are usually introduced in the final step of SPPS, after the main chain has been fully assembled and side chains are still protected. A common example is the incorporation of 5-carboxyfluorescein (5-FAM) via an Fmoc-Lys(5-FAM) building block at the N-terminus, or the coupling of biotin to an N-terminal ε-amino group of a lysine side chain using a biotin-NHS ester in a post-assembly labeling step. Because these labels are expensive and often sensitive to prolonged exposure to piperidine and acid, the incorporation step is positioned late in the synthesis, the labeling reaction is pushed to high conversion with double coupling, and the cleavage step is performed under conditions that preserve the label. Peptide bioconjugation services cover a wider scope, including click-chemistry handles (azide, alkyne, DBCO, tetrazine), metal chelators, and PEG linkers, each with its own coupling chemistry and its own set of side reactions to suppress.

Disulfide Bond Formation and Isomer Control

A disulfide bridge introduces a covalent constraint into the peptide backbone, but it also introduces the risk of disulfide scrambling, in which the two cysteine residues connect with the wrong partner and form the wrong isomer. The standard response is the use of orthogonal thiol protecting groups, which are removed in a defined sequence so that each disulfide forms at the correct time. The Trt (trityl) group is removed by TFA, the Mob (4-methoxybenzyl) group by TFA in the presence of a suitable scavenger, and the Acm (acetamidomethyl) group by iodine oxidation. A typical protocol for a two-disulfide peptide uses Trt on one pair and Acm on the other, performs the first oxidation in solution after cleavage, and then uses iodine to deprotect and close the second bridge. Where three disulfides are present, a third orthogonal group such as Meb (4-methylbenzyl) or StBu (tert-butylthio) is added. The success of a multi-disulfide peptide synthesis is measured less by overall yield and more by the ratio of the native isomer to its scrambled analogs in the crude product, and good protocols keep the native isomer as the dominant product rather than a minority.

The table below summarizes the modification classes described above, the characteristic challenge associated with each, and the synthetic strategy that is normally applied to address it.

Table.3 Common Peptide Modification Challenges and Recommended Solutions.

Common Peptide Purification Challenges and Their Solutions

Purification is the bottleneck of most custom peptide projects. The crude product is a complex mixture containing the target peptide, deletion sequences, truncated sequences, acetylated or truncated failure products, residual protecting groups, scavengers from the cleavage step, and salts from buffers and coupling reagents. The chemist's task is to convert this mixture into a single well-characterized compound at the requested purity, typically using reversed-phase HPLC as the primary tool and ion-exchange or size-exclusion chromatography as supplementary tools for specific cases.

Separating Deletion Sequences and Closely Related Impurities

Deletion sequences are the most common impurity in any SPPS crude product, and they are also the most difficult to remove because they differ from the target by only one or a few residues and tend to elute in the same chromatographic window. Two practical measures are used to manage this challenge. First, the synthesis is executed with capping at every step, which converts every failed coupling into an acetylated early-eluting impurity that does not co-elute with the target. Second, the purification gradient is developed as a shallow ramp around the target retention time, typically a 0.2–0.5 % acetonitrile per minute gradient across the region where the target elutes, so that the chromatographic separation between the target and its nearest-eluting deletion is maximized. For difficult cases, a two-dimensional strategy, in which the target fraction from a first reversed-phase run is re-purified on a different column chemistry (for example a different bonded phase, an ion-exchange column, or a different pH), can resolve impurities that co-elute on the first dimension.

Purifying Highly Hydrophobic and Aggregation-Prone Peptides

Peptides with hydrophobic patches, membrane-spanning sequences, or amphipathic helices tend to stick to reversed-phase columns, elute as broad tailing peaks, and aggregate in solution. The standard response is a different bonded phase. Where a C18 column gives poor peak shape, a C4 or phenyl column typically delivers sharper peaks and shorter retention; where acidic mobile phases promote aggregation, a neutral pH mobile phase with triethylammonium acetate buffers improves recovery. Elevated column temperature (40–60 °C) is often a powerful additional tool because it disrupts hydrophobic aggregation in the mobile phase. For the most stubborn cases, the crude peptide is dissolved in a strong denaturant such as 6 M guanidinium chloride or 8 M urea, which keeps the peptide monomeric in solution until it reaches the column and begins to partition into the stationary phase.

Improving Peptide Solubility and Recovery During Purification

Recovery loss during purification can be larger than expected, particularly for very hydrophobic peptides that precipitate on the column or stick irreversibly to frits and tubing. The practical countermeasures are simple but important. The peptide is dissolved at the highest concentration that the solution can support without visible precipitation, typically 1–5 mg/mL; the sample is filtered through a low-protein-binding membrane before injection; and the loading is held below the dynamic binding capacity of the column, which for most preparative C18 packings is roughly 5–10 mg of peptide per gram of packing. Mobile-phase additives such as 0.1 % trifluoroacetic acid are standard; for peptides that require a higher pH, 0.1 % formic acid or 10 mM ammonium acetate can substitute. After collection, fractions are screened by analytical HPLC before pooling, so that fractions containing only the target compound are combined and fractions containing mixed impurities are re-purified rather than blended.

Selecting Reversed-Phase HPLC Conditions for Difficult Peptides

Method development for reversed-phase peptide purification follows a structured sequence. The crude sample is first screened on an analytical column under a standard gradient (5–65 % acetonitrile in 0.1 % TFA over 30 minutes) to identify the retention window of the target. The gradient is then flattened in that window, the column temperature is tuned, and the mobile-phase additive is varied until the target peak is sharp and baseline-resolved from its nearest neighbors. For acidic peptides the mobile phase can be shifted to a higher pH to ionize the side chains and increase retention; for basic peptides the pH can be lowered to neutralize and increase retention. The final preparative method is scaled to the load and the column, with a linear velocity that matches the analytical method. Throughout this process, the role of the analytical method is to act as a proxy for the preparative separation, so that the same chemistry is scaled cleanly from 4.6 mm bore to 20 mm or 50 mm bore.

Table.4 Common Purification Problems and Recommended Reversed-Phase Conditions.

Using Ion-Exchange and Size-Exclusion Chromatography for Specific Cases

Reversed-phase chromatography cannot solve every separation problem. When the target peptide is highly charged and its near-eluting impurities carry similar charge, ion-exchange chromatography provides an orthogonal separation mechanism. Strong cation-exchange columns are used for basic peptides, strong anion-exchange columns for acidic peptides, and salt gradients rather than organic gradients provide the elution force. Size-exclusion chromatography is reserved for two specific cases: the removal of high-molecular-weight aggregates from the final product, and the separation of peptides that differ primarily in hydrodynamic volume, such as a stapled peptide from its linear precursor. In both cases, size-exclusion is run under non-denaturing conditions so that the relevant physical property, oligomeric state or chain compactness, controls the separation.

Removing Salts, Counterions, and Residual Reagents

Peptides purified by reversed-phase HPLC in TFA/acetonitrile mobile phases are typically recovered as their TFA salts. For most research applications this is acceptable; for quantitative assays, mass spectrometry work, and certain biological assays the TFA counterion is replaced by acetate, chloride, or another counterion through a simple ion-exchange step or a lyophilization from a dilute acid solution. Residual acetonitrile and TFA are removed by rotary evaporation or lyophilization from a volatile aqueous solution. The final product is dissolved in a small volume of dilute acetic acid or water, frozen, and lyophilized to a dry powder. The lyophilized peptide is stored at low temperature, protected from moisture, and protected from light when the sequence contains aromatic residues or fluorescent labels. Where custom purification services are engaged for difficult targets, the workflow described above is built around the specific peptide rather than applied as a generic method.

The table below consolidates the purification challenges discussed in this section, the typical chromatographic or physical signal that accompanies each one, and the recommended approach for resolving it.

Table.5 Common Peptide Purification Challenges and Recommended Approaches.

Analytical Characterization of Custom Peptides

Analytical characterization is the part of a custom peptide project that turns a powder in a vial into a documented research reagent. Three measurements together define the product: mass spectrometry confirms the molecular identity of what was synthesized, HPLC defines the chemical purity of the sample, and amino acid analysis (with sequence confirmation where needed) defines the composition and verifies that the expected residues are present in the expected ratios.

Mass Spectrometry for Peptide Identity Confirmation

Mass spectrometry is the single most informative measurement on a synthetic peptide. A monoisotopic or average molecular mass within a few ppm of the theoretical value is the first criterion for product identity. Electrospray ionization (ESI) is preferred for peptides up to about 4 kDa because it produces multiply charged ions that fall in the accessible mass range of most instruments; matrix-assisted laser desorption/ionization (MALDI) is preferred for larger peptides because it produces predominantly singly charged ions and tolerates salts and buffers better. Where the mass matches, identity is essentially confirmed. Where the mass is off by the mass of a single residue, a deletion sequence is suspected; where it is off by a phosphate or a sugar, a missed modification is suspected. Tandem mass spectrometry (MS/MS) adds sequence confirmation by fragmenting the peptide along the backbone and reading the resulting ladder of b- and y-ions, which is particularly useful when the product is a novel sequence, a multi-disulfide peptide, or a branched architecture.

HPLC for Purity Profiling and Quantification

Analytical HPLC, run under the same chromatographic conditions as the preparative method, is the standard way to assign a purity percentage to a peptide product. The integration of the main peak against the total integrated area above a defined detection threshold, typically 0.1 % of full scale, gives the chromatographic purity. The choice of detection wavelength matters: 220 nm detects the peptide bond and reports the most chemically accurate purity, while 280 nm is selective for aromatic residues and reports a biased purity that emphasizes aromatic impurities. Where the product contains a chromophore such as a fluorescent label or a UV-active modification, a secondary wavelength is recorded so that the labeled species is properly accounted for. HPLC testing on the final product is therefore both a release measurement and a stability indicator, because a pure peptide stored correctly shows a stable chromatogram across time, while a degrading peptide shows a rising impurity profile.

Amino Acid Analysis and Sequence-Related Characterization

Amino acid analysis hydrolyzes the peptide into its constituent amino acids, separates them by ion-exchange or reversed-phase chromatography, and quantifies each by UV or fluorescence detection after post-column derivatization. The result is a residue-by-residue composition that can be compared to the theoretical composition; in the best case the measured molar ratios match the expected ratios to within 10 %, and the absence of any unexpected residue confirms that the synthesis did not introduce an extraneous amino acid. For sequences where identity is in question, Edman degradation from the N-terminus reads the first 20 to 40 residues sequentially and is particularly useful for confirming the order of residues in the critical N-terminal region. For longer sequences, the combination of amino acid analysis and tandem mass spectrometry is sufficient for full characterization, and the certificate of analysis that accompanies the product combines all three measurements into a single defensible document.

The table below summarizes the analytical methods described in this section and the specific question each one answers, so that a reader can map a required deliverable to the appropriate measurement.

Table.6 Analytical Methods Commonly Used to Characterize Custom Peptides.

BOC Sciences Custom Peptide Synthesis Services

BOC Sciences operates an integrated custom peptide synthesis platform that spans sequence design, synthesis, modification, purification, and analytical characterization. Our laboratories support research and discovery teams in pharmaceutical, biotechnology, academic, and diagnostic settings, with capacity from milligram research samples to multi-gram discovery batches. Every project is assigned a dedicated technical lead who reviews the sequence, anticipates the synthetic challenges described in this article, and proposes a synthesis and purification plan that meets the requested purity and timeline.

Custom Peptide Synthesis Service Portfolio

The core service portfolio covers the full length range of standard SPPS, from short oligopeptides and epitope tags to long functional sequences assembled by fragment condensation or native chemical ligation. Standard synthesis is performed on automated Fmoc-SPPS platforms with double coupling and capping, with microwave-assisted synthesis available for difficult sequences. Resins, protecting groups, and coupling chemistries are chosen by the project lead on a per-sequence basis, and each project is supported by a chromatogram of the crude product and an analytical chromatogram of the purified product, so that the customer can verify the synthesis and purification performance independently.

Modified and Specialty Peptide Capabilities

The specialty peptide portfolio is built around the modifications described in this article. Phosphopeptides are assembled using preformed Fmoc-phospho-amino acid building blocks with HATU/HOAt coupling; glycopeptides use preformed Fmoc-glycosyl-amino acids for both O-linked and N-linked glycosylation; cyclic and macrocyclic peptides are built through on-resin cyclization or solution-phase macrocyclization; stapled peptides are produced through ring-closing metathesis on the resin or in solution; and fluorescent, biotinylated, and click-handle peptides are produced through late-stage incorporation of the label. For projects that combine several modifications, the synthesis plan is reviewed for compatibility before assembly begins, and a feasibility report is provided if any combination is expected to be unusually challenging.

Peptide Purification and Analytical Support

Purification is performed on preparative HPLC systems equipped with column ovens, automated fraction collectors, and in-line pH and conductivity monitoring. The standard workflow uses a C18 column with a 0.1 % TFA/acetonitrile gradient and a shallow ramp in the target window, with C4, phenyl, ion-exchange, and size-exclusion columns available for difficult cases. Every purified fraction is screened by analytical HPLC before pooling, every pooled sample is analyzed by mass spectrometry, and a certificate of analysis is issued with chromatograms, mass spectra, and amino acid analysis data where appropriate. Customers receive the peptide as a lyophilized powder in a sealed vial, accompanied by the full analytical package and storage recommendations specific to the sequence.

Table.7 Custom Peptide Synthesis and Related Services at BOC Sciences.

Expert Services Supporting Biomolecule Synthesis

Expert Services Supporting Synthesis Platform